Published in final edited form as:

Genet Med. 2011 September ; 13(9): 832–840. doi:10.1097/GIM.0b013e31821882b7.

Personalized Cancer Genetics Training for Personalized Medicine:

Improving community-based health care through a genetically literate workforce

Kathleen R. Blazer, EdD, MS, CGC,

Division of Clinical Cancer Genetics, 1500 East Duarte Road, Duarte, CA 91010

Deborah J. MacDonald, PhD, APNG,

Division of Clinical Cancer Genetics, 1500 East Duarte Road, Duarte, CA 91010

Julie O. Culver, MS, CGC,

Division of Clinical Cancer Genetics, 1500 East Duarte Road, Duarte, CA 91010

Carin R. Huizenga, MS, CGC,

Division of Clinical Cancer Genetics, 1500 East Duarte Road, Duarte, CA 91010

Robert J. Morgan, MD, FACP,

Department of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010

Gwen C. Uman, PhD, RN, and

Vital Research, 6380 Wilshire Blvd, Suite 1609, Los Angeles, CA 90048

Jeffrey N. Weitzel, MD

Division of Clinical Cancer Genetics, 1500 East Duarte Road, Duarte, CA 91010; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010

Abstract

Purpose—To assess the impact of a multi-modal interdisciplinary course in genetic cancer risk assessment (GCRA) and research collaboration for community-based clinicians. Clinicians are increasingly requested to conduct GCRA, but many are inadequately prepared to provide these services.

Methods—A prospective analysis of 131 participants (48 physicians, 41 advanced-practice nurses and 42 genetic counselors) from community settings across the U.S. The course was delivered in three phases: distance didactic learning, face-to-face training and 12 months of Web-based professional development activities to support integration of skills into practice. Cancer

Corresponding Author: Jeffrey N. Weitzel, MD, Division of Clinical Cancer Genetics, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010 (jweitzel@coh.org), (626) 256-8662 Office, (626) 930-5495 FAX.

Author Contributions: Kathleen R. Blazer and Jeffrey N. Weitzel had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.

Conflict of Interest: The authors assert that no commercial association poses or creates a conflict of interest with the information presented in this manuscript.

Financial Disclosures: None reported.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

genetics knowledge, skills, professional self-efficacy and practice changes were measured at baseline, immediate- and 14-months-post course.

Results—Knowledge, skills and self-efficacy scores were significantly different between practice disciplines; however, post scores increased significantly overall and for each discipline ($p < .001$). Fourteen-month practice outcomes reflect significant increases in provision of GCRA services ($p = .018$), dissemination of cancer prevention information ($p = .005$) and high-risk screening recommendations ($p = .004$) to patients, patient enrollment in research ($p = .013$), and educational outreach about GCRA ($p = .003$).

Conclusions—Results support the efficacy of the multi-modal course as a tool to develop a genetically literate workforce. Sustained alumni participation in Web-based professional development activities has evolved into a distance-mediated *Community of Practice* in clinical cancer genetics, modeling the lifelong learning goals envisioned by leading CME stakeholders.

Keywords

Cancer Genetics; Education; Personalized Medicine

INTRODUCTION

The rapid evolution of genetic and genomic technologies has revolutionized our approach to cancer risk assessment, screening, prevention and targeted cancer therapies, heralding the era of personalized medicine. Genetic cancer risk assessment (GCRA) is a specialized clinical service to identify and prescribe high-risk screening and prevention care for individuals with increased cancer risk. Initially delivered primarily through academic health centers, commercial availability of genetic testing, direct-to-physician and direct-to-patient marketing have accelerated the uptake of predictive testing for cancer risk in the community setting, where clinicians are often inadequately prepared to select and apply genetic tests, and interpret their results.¹⁻⁶

In response to the national need for specialized training in GCRA, the Division of Clinical Cancer Genetics (CCG) at City of Hope Medical Center (COH) developed a National Cancer Institute-funded (R25 CA112486) Intensive Course in Community Cancer Genetics and Research Training for community-based clinicians. The goals of the course are to increase the number of clinicians with practitioner-level competence in GCRA and to promote community-based research participation. These goals are accomplished through a three-phase continuing medical education (CME)-accredited program of distance didactic learning, interdisciplinary face-to-face training and continuing professional development activities to support the integration of high-quality, evidence-based GCRA services and research into practice. Development of the multimodal course was guided by the tenets of adult learning and medical education theory.⁷⁻¹⁶ The course design was also informed by feedback from participants in a two-week traditional face-to-face pilot course who identified interdisciplinary case-based training and practice-centered support as the greatest strengths of the course, but found the two weeks of face-to-face training challenging in terms of the compressed content and time away from practice and family.¹⁷

This paper reports the impact of the course on clinician knowledge, skills, professional self-efficacy and practice change, and describes the evolution of a distance-mediated *Community of Practice* in clinical cancer genetics to support enduring professional development for community-based clinicians. The innovative course design models the goals of lifelong learning and improved patient care envisioned by the Institute of Medicine (IOM) and other leading CME stakeholders.¹⁸⁻²²

MATERIALS AND METHODS

Course Description

The multi-modal course incorporates the curricular and training resources of the City of Hope *Cancer Genetics Education Program*,²³⁻²⁵ clinical expertise from the CCG *Cancer Screening & Prevention Program Network*, which has provided cancer risk assessment services to more than 7,000 at-risk families,²⁶ and institutional research and informatics resources. The didactic curriculum, previously described,¹⁷ incorporates key elements of the American Society of Clinical Oncologists (ASCO) cancer genetics curriculum²⁷⁻²⁸ and encompasses content covering basic genetics and oncology, documentation and verification of the family cancer history, hereditary syndrome recognition, genetic testing strategy, test results interpretation and communication, development of evidence-based personalized risk management guidelines, ethical, legal and social implications (ELSI), and applied research methodology. In the initial course session (2006), the curriculum was delivered through traditional face-to-face lectures that were digitally recorded and converted to *QuickTime*TM (Apple Inc., Cupertino, CA) video. Recorded sessions were distributed via CD-ROMs and Web-based download for distance learning in subsequent sessions (2007-2010). The multimodal course curriculum was delivered in three phases over a 14-month period (Figure 1). *Phase 1* includes 27 modules of distance-learning didactics delivered over two months, supplemented with discussion board and weekly two-hour Web conference sessions for evidence-based updates on each topic. *Phase 2* consists of five days of face-to-face interdisciplinary training at the COH campus in Duarte, California. Participants are awarded up to 90.5 CME/CEU credit hours upon completion of *Phases 1* and *2*. *Phase 3* comprises 12 months of prescribed professional development activities to facilitate the integration of new learning and skills into practice.

Phase 3 professional development activities are centered on participation in two CME-accredited Web conference series hosted by the interdisciplinary course faculty and facilitated by *Microsoft Live*TM (Microsoft Corporation, Redmond, WA) interface: *Clinical Cancer Genetics (CCG) Working Group* and *Topics in Cancer Genetic Research (TICGR)*. *CCG Working Group* is a weekly two-hour interdisciplinary cancer genetics case conference series in which COH and affiliated clinicians across the U.S. present cases from their community practices to discuss cancer risk assessment, surveillance, risk management and research eligibility for cases covering the full spectrum of hereditary cancers. *TICGR* is a weekly one-hour Web conference seminar series focused on timely issues in cancer genetics research presented by COH faculty, guest lecturers from other academic institutions, and clinical affiliates. Among prescribed *Phase 3* activities, course alumni are expected to participate and present cases from their practices in a minimum of two *Working Group* sessions, participate in at least two and present at one *TICGR* session, and disseminate evidence-based GCRA information in their community settings through professional and lay presentations.

Participants and Recruitment

The course is purposefully designed to bring clinicians from different disciplines and practice backgrounds together for collaborative interdisciplinary GCRA training. Physicians (MDs), masters-degreed genetic counselors (GCs), advanced-practice nurses (APNs) or other advanced-degreed clinicians were competitively selected by an interdisciplinary committee of course faculty (one onco-geneticist, one PhD nurse and two board-certified GCs). Selection criteria were academic and clinical background, need for GCRA services and/or an underserved population in their practice area, and documentation of institutional support for participants to initiate or expand their GCRA practices upon return to their community practice settings. Announcements for the course were delivered by email,

listservs and at annual meetings for national medical societies and organizations, and posted on the course Website.

Instruments

Course assessment and evaluation instruments address five of the seven levels of expanded CME outcomes described by Moore, et al. (2009) (listed in Figure 1) and recently endorsed by leading CME stakeholders as essential to quality assessment of all continuing medical education and professional development activities.^{18, 21, 29} The learning and skills outcomes assessment instruments listed below were administered via *SelectSurvey.Net 2006* (ClassApps.com, Overland Park, KS) at the time points indicated in Figure 1.

Cancer Genetics Knowledge Test (Assessment Levels 3A/B)—A 96-item multiple choice test (coefficient alpha of .70 for internal consistency reliability) covering eight content domains: basic genetics, cancer history documentation, cancer genetics, oncology, recognition of hereditary cancer features, differential diagnoses, genetic testing strategy/test interpretation, ELSI and human subjects protections, administered at baseline (pre-course) and post *Phase 2* (final day of face-to-face training).

Professional Self-Efficacy Survey (Assessment Level 4)—A 34-item Likert scale survey measuring participant perceptions about their knowledge and skills in six core competency domains: genetics/oncology, hereditary cancer risk assessment, genetic testing strategy/test interpretation, risk management, counseling/ELSI, and research collaboration, administered at baseline and post *Phases 2* (immediate post course) and *3* (14 months post course). Respondents select from five response choices per item, ranging from 0 = No Experience/Can't Assess, to 5 = Very Confident. Reliability of the domains ranged from coefficient alpha = .77 to .97, and was .97 for the overall composite score.

Case-based Skills Scenarios (Assessment Level 4)—Beginning with the 2008 course session, skills related to the process of cancer history documentation and verification, hereditary cancer risk assessment, and ordering and interpreting genetic tests were assessed using two case scenarios of similar complexity and content, followed by open-ended questions. Scenarios were administered at baseline and post *Phase 2* and were scored independently by two CCG clinical faculty members using a point system based on accuracy, breadth and depth of responses in three knowledge/skills domains: pedigree construction, cancer history documentation/verification, and risk assessment/testing strategy. Subscores were combined for a total score. Twelve randomly-selected pre and post scenario sets were scored by both raters to provide an estimate of inter-rater agreement. Intra-class correlation coefficients (ICCs) for baseline and post scores were high (Baseline ICC = .98; Post ICC = .99) and significantly different than zero ($p < .001$).

Practice and Professional Development Survey (Assessment Level 5)—Comparisons of participant-reported baseline and post *Phase 3* practice changes were assessed based on number of patients seen for GCRA services, number of patients given cancer prevention information, provision of personalized risk management recommendations, facilitation of patient participation in research, professional and lay educational outreach, and participation in prescribed *Phase 3* activities (*CCG Working Group* and *TICGR* Web conference participation and presentations).

Practice and Professional Development Tracking Log (Assessment Level 5)—Participation in *Phase 3* practice and professional development activities were also tracked by the host institution using *Microsoft Live* electronic attendance logs and summarized at the completion of *Phase 3*. Continued participation in these activities beyond *Phase 3* was

also tracked to examine longer-term professional development behaviors and practice activities (GCRA case presentations and enrollment of patients in cancer genetics research registries).

Statistical Analyses

All data were entered into spreadsheets, audited for accuracy, and imported into SPSS v18.0 (Statistical Package for the Social Sciences, SPSS, Inc., Chicago, IL, USA) for statistical analysis. The pre and post knowledge tests were scored according to the answer keys. Knowledge gains in the first year of the course (delivered entirely face-to-face) and the year of transition to the multi-modal design were compared to assure equal learning efficacy. The self-efficacy instrument subscales were computed based on content validity: genetics and oncology, hereditary risk, testing strategies, risk management, counseling/ELSI, research collaboration, and total score. Total scores were used for statistical comparisons.

Descriptive statistics were computed for all scores and Practice Survey items. Two-way repeated measures analysis of variance (ANOVA) was used to compare knowledge change by course session and by practice discipline. Multivariate ANOVA was used to compare self-efficacy subscale scores by session and by discipline. Analyses on the three measurement points for self-efficacy incorporated the participants (n=52) who completed the post *Phase 3* professional practice survey. A Bonferroni correction was used to adjust for experiment-wise inflation error. The McNemar test or paired t-tests were used to compare differences in dichotomous or continuous practice survey items, respectively. A two-way repeated measures ANOVA was used to compare baseline vs. post *Phase 2* score performance by discipline on case-based skills scenarios.

RESULTS

Descriptive demographics

Course announcements for sessions held between January 2006 and March 2010 yielded 402 formal applicants. Of these, 135 were competitively selected to participate, 131 accepted and three deferred participation to a later session due to schedule conflicts. Participant demographics are summarized in Table 1. All 131 participants (48 MDs, 41 APNs, 42 GCs) completed all *Phase 1* distance learning and *Phase 2* face-to-face training requirements. One-hundred twenty-four participants practiced in the U.S (43 states represented) and seven (5.3%) were from countries outside of the U.S. Participants were predominantly female (86%), Caucasian (82%), had more than 10 years of clinical experience (58%), and were providing GCRA as part of their practice at the time they participated in the course (76%). Nineteen percent reported African-American or Hispanic ancestry and 57% practiced in a geographically underserved area and/or provided minority outreach services. MDs, APNs and GCs were represented in roughly equal proportions for all sessions. Twelve (six pairs) of clinicians trained as teams, wherein a physician and mid-level APN or GC colleague from the same practice setting completed the course together.

No significant differences were evidenced in knowledge acquisition or professional self-efficacy between the 2006 session (delivered through a traditional lecture-based format) and the 2007 session (conversion to the 3-phase multimodal format). As shown in Figure 2a, Level 3A/B declarative/procedural knowledge significantly increased from baseline to post *Phase 2* among participants overall ($p<.001$) and in all sessions (mean increase 28%; range 12.2%-38.5%). By-discipline comparisons of baseline to post course knowledge demonstrated statistically-significant increases for GCs, MDs and APNs ($p<.001$ for all disciplines). Differences in between-discipline comparisons of baseline knowledge scores were statistically significant ($p<.001$), with the highest baseline scores among GCs (72%),

followed by MDs (67%) and APNs (59%). Post-course knowledge scores for GCs and MDs (85%) were significantly higher ($p<.001$) than for APNs (75%).

As illustrated in Figure 2b, Level 4 assessment of competency and skills in an education setting, measured by case-based skills scenarios, increased significantly from baseline to post-*Phase 2* for all disciplines ($p<.001$ for MDs and APNs; $p=.007$ for GCs). Between-discipline comparisons of skills scores were significantly different, with the highest baseline scores attained by GCs (59%), followed by APNs (51%) and MDs (44%). GC and APN post-course skills scores were significantly higher (64% for both) than post scores for MDs (58%).

Table 2 summarizes Level 4 changes in self-efficacy overall and by practice discipline. All 105 participants who reached the post *Phase 3* time point (14 months from baseline) at the time of analysis had completed baseline and post *Phase 2* professional self-efficacy surveys. Of these, 52 (50% response rate) also completed the post *Phase 3* self-efficacy survey. Overall and subscale self-efficacy scores increased significantly from baseline to the post-*Phase 2* measurement for all disciplines ($p<.001$). These increases were maintained or further increased at the post-*Phase 3* time point. Between-discipline comparisons of self-efficacy scores demonstrated a significant interaction effect in the overall ($p=.003$) and three of the six subscale scores: genetics/oncology ($p=.002$), hereditary cancer risk assessment ($p=.001$) and test strategy/interpretation ($p<.001$).

More than 85% of alumni fulfilled course-prescribed Web-based professional development activities (*Working Group* and *TICGR* participation), and all 57 participants (54% response rate) who completed post-course professional practice surveys completed *all* prescribed *Phase 3* Level professional development activities. As summarized in Table 3, there were significant baseline-to post *Phase 3* increases in the number of patients seen for GCRA ($p=.018$), number of patients given information or resources for cancer prevention studies ($p=.005$), and number of patients enrolled in hereditary cancer registries ($p=.007$). There were also significant increases in the number of participants who provided high-risk screening and prevention recommendations to patients ($p=.004$), and who conducted professional education ($p=.003$) and lay educational outreach ($p=.041$). Additionally, ongoing professional development tracking revealed that more than 30% of alumni continue to participate in *Phase 3* Web-based professional development activities beyond the prescribed 12-month period. Course alumni have presented more than 800 cases from their community-based practices in weekly *CCG Working Group* Web conferences and have enrolled more than 2,000 patients in cancer genetics research registries or protocols. Moreover, 14 course alumni (eight MDs, three APNs and three GCs) established formal inter-institutional collaborations with the COH hereditary cancer registry³⁰ to promote community-based accrual of patients into cancer research protocols. Six additional alumni (four APNs and two GCs) attempted to develop collaborations but were unable to work through administrative and regulatory barriers (such as lack of support by their administration or prohibitive IRB fees).

DISCUSSION

The forces of genetic discovery and direct-to-consumer and physician marketing are driving increasing demands for genetic tests that predict health risks.¹⁻⁶ Technology and market-driven pressures notwithstanding, leading oncology and genetics stakeholders strongly recommend that predictive genetic testing be conducted by *qualified* cancer genetics providers.³¹⁻³³ Oncology, genetics, nursing and government health organizations and some academic institutions offer cancer genetics seminars, workshops and Web-based GCRA resources, and the ASCO Cancer Genetics & Cancer Predisposition Testing Curriculum is a

self-teaching resource for oncologists and other health care providers.²⁷⁻²⁸ At present, even within the field of medical genetics, there is no practice credential offered for the subspecialty of cancer genetics. Programs like the Intensive Course in Community Cancer Genetics and Research Training described in this report are therefore needed to train clinicians for practitioner-level competence in GCRA.

The course outcomes demonstrate an effective transition from the face-to-face pilot course that served as its foundation¹⁷ to a multi-modal three-phase course that combines the flexibility and convenience of distance learning with interdisciplinary face-to-face training and continuing practice-centered support. The course design was informed by the tenets of adult learning theory,³⁴⁻³⁵ evidence demonstrating the ineffectiveness of traditional, didactic-focused approaches to CME,³⁶⁻³⁹ and calls from leading stakeholders across the CME enterprise for practice-centered models of learning that enhance quality health care, support professional activities and produce measurable outcomes.^{13, 18, 40-42}

The majority of participants in the six sessions included in this analysis were female, in part reflecting the dominance of females in the genetic counseling and nursing professions. Despite the fact that 29/48 (60%) of the physician participants were also female (possibly reflecting a motivation for training among clinicians who practice in women's health programs, where market-driven demands for BRCA testing are concentrated), there has been a steady increase in the number of male physicians applying to and participating in the course over time. For example, of the 21 participants in the Jan-March 2011 session, eight of the 14 physicians are male (four are providing GCRA services within women's health programs, and four are training to develop GCRA programs in broader-spectrum practice settings).

Significant pre-to-post gains were demonstrated overall and by practice discipline in procedural knowledge, professional self-efficacy (a recognized surrogate for actual performance),⁴³⁻⁴⁵ and case-based skills. Similar to outcomes from the pilot intensive course, GCs had the highest baseline scores on all measures, and post-course knowledge scores were significantly higher among GCs and MDs compared with APNs.¹⁷ However, MDs scored significantly lower than GCs and APNs on post case-based skills. Although generally accurate, open-ended responses by some MDs were cursory and lacked detail, while GCs and APNs more often provided detailed pedigrees and nuanced responses. A more in-depth review of the case scenario responses may help elucidate ways to improve methods for assessing GCRA skills outcomes and better identify discipline-specific learning needs.

Beyond knowledge and skills acquisition, 14-month post-course assessments demonstrated anticipated gains in the delivery of GCRA services, educational activities, and research participation among course alumni. Although only 50% of the 105 post-*Phase 3* alumni completed all *Phase 3* professional development practice and self efficacy surveys, internal tracking of engagement in *CCG Working Group* and *TICGR* conferences revealed that 85% fulfilled or surpassed the minimum prescribed participation in these activities. Tracking records and alumni feedback suggest that clinicians who practice in procedurally-dominated specialties (such as surgeons and medical oncologists) are less likely to participate fully in post-course professional development activities, in large part due to time constraints and schedule conflicts. Among the six pairs of clinicians who trained as teams, the mid-level clinicians more frequently engaged in *Phase 3* Web-based activities and continue to represent the team in these activities beyond the required *Phase 3* timeframe. This finding reflects the value of our multidisciplinary training model and supports the rationale for cross-disciplinary team learning described as a priority by the IOM (2010).

An associated observation is that while many mid-level clinicians expressed interest in establishing formal cancer genetics research collaborations after completing the course, few were able to get through the regulatory process required for participation in the research network. This suggests that a physician champion is more likely to be empowered to commit the practice, time and resources required, and to successfully navigate the administrative and regulatory process involved in establishing these collaborations, and points to the value of the multidisciplinary team in the development of GCRA programs.

The growing roster of course alumni who participate in *Phase 3 CCG Working Group* and other professional development activities beyond the prescribed 12-month *Phase 3* period is an unexpected outgrowth of the course experience. Findings from an action research project conducted with course alumni revealed that many continue to participate in *Phase 3* activities to support evidence-based GCRA patient care and research collaboration in their practices.⁴⁶

Situated learning theory⁴⁷ describes how learning is transformative when professionals connected by common practice-centered needs and learning goals come together in informal Community of Practice (CoP) settings. Through regular CoP participation, new learners move from peripheral to deeper engagement in the learning culture, eventually assuming the role of expert.⁴⁸ Ongoing participation in CCG Web-based activities by a motivated subset of course alumni extends the impact of the course experience beyond near-term changes in knowledge and skills, and now forms the nexus of a thriving distance-mediated CoP in clinical cancer genetics for clinicians across the U.S.

CoPs have been a recognized professional development resource in the business and education sectors for decades, but the study of their efficacy in health care settings has only gained momentum in recent years.⁴⁹⁻⁵⁰ Increases in professional self-efficacy scores at 14 months post course may be attributed in part to participation in CoP activities. Presentation of more than 800 GCRA cases by course alumni provides an objective measure of CME assessment Level 5 performance in practice, tracked through engagement in enduring CoP activities that directly inform evidence-based patient care. CCG clinical faculty have observed progressive improvements in GCRA-specific skills among alumni who participate regularly in COH-hosted CoP activities. Future efforts will expand examination of the effects of enduring CoP participation on Level 5 performance outcomes, and additional methods are currently being piloted for longitudinal Level 6 patient health outcomes assessments. Additional interfaces, including a Web-based and topic-specific discussion group and listserv, are also under development to augment the distance-mediated CoP experience.

Limitations

The majority of course participants had training in oncology or genetics; consequently, generalizability of the findings and adaptability to more primary care audiences is uncertain. Although not analyzed separately, our limited experience with training primary care and ob-gyn clinicians (n=13) suggests similar gains in knowledge, professional self-efficacy and skills for these participants. The breadth of topics covered in the course is comprehensive, and might be beyond the scope of need for some clinicians, but the modular nature of the course lends itself to tailoring for focused interest tracks, such as a breast cancer track for clinicians working exclusively in a breast center setting. While the case scenario instrument has demonstrated content validity and scoring reproducibility, additional validation is warranted with a more diverse set of clinicians.

Conclusions

The significant impact of the COH *Community Cancer Genetics and Research Training* initiative on multiple practice-based outcomes supports the efficacy of the multi-modal course design for clinical proficiency training in GCRA. The course was originally funded to provide for 15 competitively-selected community-based participants yearly. However, CCG Division resources, aided by American Recovery and Reinvestment Act funds (ARRA #3R25CA112486), have been extended to help address the steady increase in demand for cancer genetics training. To date, the expanded program has trained 131 clinicians from 43 states across the U.S.—more than double the initial target accrual goal; however, there is still unmet need for GCRA training both here and abroad. Seven clinicians representing clinical cancer genetics initiatives in Brazil, Canada, Chile, Hong Kong and Spain completed the course and continue to participate in Web-based CoP activities introduced through the course. Access to the genetic and genomic tools of personalized medicine is nascent in many of these regions. Future efforts should include locally relevant cancer genetics training to address disparities in other countries.

As recently outlined by the IOM, leading CME stakeholders across the full spectrum of healthcare have set forth a mandate to promote CME activities that are purposefully designed to improve practice-based competencies and address lifelong professional learning needs.^{18-22, 51} Beyond the near-term learning efficacy of the course, initial assessments of sustained participation in CoP activities demonstrate the potential of Web-based CME for continuing professional development.

The multi-modal, multi-metric design of the course and its distance-mediated CoP successfully leverage the expertise of the academic health center to help address the need for a genetically literate workforce. This dynamic continuum of advanced training and enduring practice-centered support models the vision of lifelong professional learning that promotes quality care and improved patient outcomes. Future efforts will focus on the direct impact of CoP-generated learning with changes in patient outcomes, in alignment with the highest levels of CME accountability.

Acknowledgments

The authors particularly wish to acknowledge Katie Calcagno, Jonathan Espenschied, Hazel Mariveles, Gloria Nunez, Shawntel Payton, Jerry Ruiz, Sharon Sand, and Tracy Sulkin for assistance with program coordination, data collection and manuscript preparation. Faculty who contributed to the curriculum also included Kimberly Banks, MS, CGC; Cathy Cole, RNC, NP, MPH; Allan Ebbin, MD, MPH; Josef Herzog, BS; Lucille Leong, MD; Katrina Lowstuter, MS, CGC; Susan Neuhausen, PhD; Joyce Niland, PhD; Raquel Ogaz, BA; Gwenn Oki, MPH; Melanie Palomares, MD, MPH; Gloria Petersen, PhD; Charite Ricker, MS, CGC; Juan-Sebastian Saldivar, MD; Sharon Sand, BS, CCRP; April Sorrell, MD; and Sharon Wilczinski, MD, PhD. Finally, we thank the course participants who challenged the instructors to make learning relevant to their practices and endured detailed metrics, contributing to the organic evolution of a quality community of practice.

Research Funding/Support: The research and education programs described in this manuscript were supported in part by National Cancer Institute Grants R25 CA75131, R25 CA112486 (including an ARRA supplement), 3R25 CA112486-05S1, R25 CA85771, and RC4CA153828 (Clinical Cancer Genetics Community Network: A Sustainable Research Partnership), and by Project #MCHG-51 from the Maternal and Child Health Bureau (Title V, Social Security Act), Health Resources and Services Administration, Department of Health and Human Services, and by State of California Cancer Research Program Grant #99-86874.

Role of the Sponsors: The funders had no role in the design and conduct of the study, analysis and interpretation of the data, or preparation, review, or approval of the manuscript.

REFERENCES

1. Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. *Nature*. 2009; 461(7265):724–726. [PubMed: 19812653]

2. Evans JP. Health care in the age of genetic medicine. *JAMA*. 2007; 298(22):2670–2672. [PubMed: 18073364]
3. Myers MF, Chang MH, Jorgensen C, et al. Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians' knowledge and practices. *Genet Med*. 2006; 8(6):361–370. [PubMed: 16778598]
4. Murphy SAR, Freed JS. Healthcare's ascension to patient-centered genomic care. *Pers Med*. 2008; 5(5):505–509.
5. Vadaparampil ST, Wideroff L, Olson L, Viswanath K, Freedman AN. Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. *Am. J. Med. Genet*. 2005; 135A(1):41–46. [PubMed: 15810000]
6. Wolfberg AJ. Genes on the Web--direct-to-consumer marketing of genetic testing. *N Eng. J Med*. 2006; 355(6):543–545.
7. Merriam SB. *Andragogy and Self-Directed Learning: Pillars of Adult Learning Theory*. New Directions for Adult and Continuing Education. 2001; 89(89):3–13.
8. Schön, DA. *The Reflective Practitioner: How Professionals Think in Action*. Temple Smith; London, UK: 1983.
9. Segrave S, Holt D. *Contemporary Learning Environments: Designing e-Learning for Education in the Professions*. Distance Education. 2003; 24(1):7–24.
10. Slotnick HB. How doctors learn: the role of clinical problems across the medical school-to-practice continuum. *Acad Med Jan*. 1996; 71(1):28–34.
11. Spencer JA, Jordan RK. Learner centered approaches in medical education. *Br Med J*. 1999; 318:1280–1283. [PubMed: 10231266]
12. Barnes BE. Creating the practice-learning environment: using information technology to support a new model of continuing medical education. *Acad Med*. 1998; 73(3):278–281. [PubMed: 9526455]
13. Bennett N, Davis D, Easterling W, et al. Continuing medical education: A new vision of the professional development of physicians. *Acad Med*. 2000; 75(12):1167–1172. [PubMed: 11112712]
14. Jay SJ, Anderson JG. Continuing Medical Education and Public Policy in an Era of Health Care Reform. *J Contin Educ Health Prof*. 1993; 13(3):195–209.
15. Leist JC, Pennington FC. Practice-based learning and improvement: an introduction. *J Contin Educ Health Prof*. 2003; 23(Suppl 1):S4–5. [PubMed: 14666827]
16. Moore DE, Green JS, Jay SJ, Leist JC, Maitland FM. Creating a new paradigm for CME: Seizing opportunities within the health care revolution. *J Contin Educ Health Prof*. 1994; 14(1):4–31.
17. Blazer KR, MacDonald DJ, Ricker C, Sand S, Uman GC, Weitzel JN. Outcomes from intensive training in genetic cancer risk counseling for clinicians. *Genet Med*. 2005; 7(1):40–47. [PubMed: 15654227]
18. IOM (Institute of Medicine). *Redesigning continuing education in the health professions*. National Academies Press; Washington, DC: 2010. Retrieved from <http://www.nap.edu/catalog/12704.html>
19. Kuehn BM. IOM: Improve clinician CME system. *JAMA*. 2010; 303(8):716. [PubMed: 20179277]
20. Jackson MJ, Gallis HA, Gilman SC, et al. The need for specialty curricula based on core competencies: A white paper of the Conjoint Committee on Continuing Medical Education. *J Contin Educ Health Prof*. 2007; 27(2):124–128. [PubMed: 17576626]
21. Moore DE Jr. Green JS, Gallis HA. Achieving desired results and improved outcomes: Integrating planning and assessment throughout learning activities. *J Contin Educ Health Prof*. 2009; 29(1):1–15. [PubMed: 19288562]
22. Leist JC, Green JS. Congress 2000: A continuing medical education summit with implications for the future. *J Contin Educ Health Prof*. 2000; 20(4):247–251. [PubMed: 11201064]
23. Blazer KR, MacDonald DJ, Justus KA, et al. Creating tomorrow's leaders in cancer prevention: A novel interdisciplinary career development program in cancer genetics research. *J Cancer Educ*. 2006; 21(4):216–222. [PubMed: 17542713]

24. Blazer KR, Grant M, Sand SR, MacDonald DJ, Uman GC, Weitzel JN. Effects of a cancer genetics education programme on clinicians knowledge and practice. *J Med Genet.* 2004; 41(7):518–522. [PubMed: 15235022]
25. Blazer KR, Grant M, Sand SR, et al. Development of a cancer genetics education program for clinicians. *J Cancer Educ.* 2002; 17(2):69–73. [PubMed: 12092855]
26. MacDonald, DJ. Establishing a Cancer Genetics Service. In: Kuerer, H., editor. *Kuerer's Breast Surgical Oncology*. McGraw-Hill; New York, NY: 2010.
27. ASCO. Cancer Genetics & Cancer Predisposition Testing. ASCO Curriculum. Vol. Vol 1 & 2. American Society of Clinical Oncology; Alexandria, VA: 1998.
28. ASCO. Cancer Genetics & Cancer Predisposition Testing. 2nd ed. ASCO Publishing; Alexandria, VA: 2004.
29. ACCME. [Accessed 2010] ACCME Guide to the Accreditation Process: Demonstrating the Implementation of the ACCME's Updated Accreditation Criteria. 2009. Retrieved from: <http://www.accme.org/index.cfm/fa/AccreditationProcess.home/AccreditationProcess.cfm>
30. MacDonald DJ, Blazer KR, Weitzel JN. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: The power of partnership. *J Natl Compr Canc Netw.* 2010; 8(5):615–624. [PubMed: 20495088]
31. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology Policy Statement Update: Genetic and genomic testing for cancer susceptibility. *J Clin Oncol.* 2010; 28(5):893–901. [PubMed: 20065170]
32. ONS. [Accessed 2010] Cancer Predisposition Genetic Testing and Risk Assessment Counseling. Available at: <http://www.ons.org/Publications/media/ons/docs/positions/cancerpredisposition.pdf>
33. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors. *J Genet Couns.* 2004; 13(2):83–114. 2004. [PubMed: 15604628]
34. Shreeve MW. Beyond the didactic classroom: educational models to encourage active student involvement in learning. *J Chiropr Educ.* 2008; 22(1):23–28. [PubMed: 18483586]
35. Merriam, SB.; Caffarella, RS. *Learning in Adulthood: A Comprehensive Guide*. Josey-Bass; San Francisco, CA: 1999.
36. Davis D, O'Brien MA, Freemantle N, Wolf FM, Mazmanian P, Taylor-Vaisey A. Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? *JAMA.* 1999; 282(9): 867–874. [PubMed: 10478694]
37. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance: A systematic review of the effect of continuing medical education strategies. *JAMA.* 1995; 274(9): 700–705. [PubMed: 7650822]
38. Mansouri M, Lockyer J. A meta-analysis of continuing medical education effectiveness. *J Contin Educ Health Prof.* 2007; 27(1):6–15. [PubMed: 17385735]
39. Tian J, Atkinson NL, Portnoy B, Gold RS. A systematic review of evaluation in formal continuing medical education. *J Contin Educ Health Prof.* 2007; 27(1):16–27. [PubMed: 17385741]
40. Davis NL, Willis CE. A new metric for continuing medical education credit. *J Contin Educ Health Prof.* 2004; 24(3):139–144. [PubMed: 15490545]
41. Spivey BE. Continuing medical education in the United States: Why it needs reform and how we propose to accomplish it. *J Contin Educ Health Prof.* 2005; 25(3):134–143. [PubMed: 16173072]
42. Miller SH. American Board of Medical Specialties and repositioning for excellence in lifelong learning: Maintenance of certification. *J Contin Educ Health Prof.* 2005; 25(3):151–156. [PubMed: 16173049]
43. Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. *Psychol Rev.* 1977; 84(2):191–215. [PubMed: 847061]
44. Bandura A. The assessment and predictive generality of self-percepts of efficacy. *J Behav Ther Exp Psychiatry.* 1982; 13(3):195–199. [PubMed: 7142408]
45. Umble KE, Cervero RM, Yang B, Atkinson WL. Effects of traditional classroom and distance continuing education: A theory-driven evaluation of a vaccine-preventable diseases course. *Am J Public Health.* 2000; 90(8):1218–1224. [PubMed: 10937000]

46. Blazer, KR.; Sand, S.; Hilario, J.; Weitzel, JN. Using action research to evaluate and innovate a program of personalized cancer genetics training for personalized medicine. Paper presented at the AACE International Cancer Education Conference: The Art and Science of Cancer Education and Evaluation; Houston, TX. 2009;
47. Lave, J.; Wenger, E. Situated Learning: Legitimate peripheral participation. Cambridge University Press; Cambridge, UK: 1991.
48. Wenger, E. Communities of Practice: Learning, Meaning and Identity. Cambridge University Press; Cambridge, UK: 1998.
49. Li LC, Grimshaw JM, Nielsen C, Judd M, Coyte PC, Graham ID. Use of communities of practice in business and health care sectors: A systematic review. *Implement Sci.* 2009; 4(27)
50. Wenger, E.; McDermott, R.; Snyder, W. Cultivating Communities of Practice: A Guide to Managing Knowledge. Harvard Business School Press; Boston, MA: 2002.
51. Leist JC. Accreditation: Standards for quality continuing professional development. *J Vet Med Educ.* 2003; 30(1):13–18. [PubMed: 12737155]

Figure 1.

Multi-modal Delivery and Outcomes Assessment Schema for the City of Hope Intensive Course in Community Cancer Genetics and Research Training. The course promotes interdisciplinary knowledge acquisition, case-based skills development and integration of new knowledge and skills into practice through a combined program of synchronous (Web conferencing) and asynchronous (discussion board) distance learning, and traditional face-to-face training workshops. Alumni are invited to participate in CME-accredited professional development activities, including *CCG Working Group* (case conferencing) and *TICGR* (lecture and journal club) Web conferences, beyond the year prescribed by the course, as part of a growing distance-mediated clinical cancer genetics Community of Practice (CoP). Using the framework of improved CME outcomes described by Moore, et al. (2009),²¹ multiple assessments in *Phases 1-3* of the course go beyond Level 1-3A assessments of participation, satisfaction and declarative knowledge (outcomes most frequently assessed in CME learning activities) to include assessments of procedural knowledge (Level 3B), competence in the learning environment (Level 4), and longitudinal performance in practice outcomes (Level 5). Ongoing tracking of alumni practice activities after completion of prescribed *Phase 3* professional development tracking provides an objective source of long-term patient health outcomes (Level 6), which are currently under development.

Figure 2a and 2b.
Intensive Course Knowledge and Skills Outcomes Overall and by Practice Discipline

Table 1

Participant Demographics and Baseline Clinical Characteristics

Variable	Physician (MD) ^a N=48 (36.6%)	Advanced Practice Nurse N=41 (31.3%)	Genetic Counselor N=42 (32.1%)	Total N=131 (100%)
Gender				
Male	19 (39.6%)	0	0	19 (14.5%)
Female	29 (60.4%)	41 (100%)	42 (100%)	112 (85.5%)
Race/Ethnicity				
American Indian/Alaska Native	0	1 (2.4%)	0	1 (0.76%)
Asian	3 (6.25%)	2 (4.88%)	3 (6.35%)	8 (6.12%)
Black/African American	5 (10.4%)	1(2.4%)	4 (9.53%)	10 (7.63%)
Caucasian	40 (83.3%)	34 (82.9%)	33 (78.6%)	107 (81.7%)
Hispanic/Latino	5 (10.4%)	7 (17.1%)	3 (7.14%)	15 (11.5%)
Practice Setting				
Academic Institution/University	13 (27.1%)	7 (17.1%)	9 (21.4%)	29 (22.1%)
Community Based Hospital	22 (45.8%)	16 (39.0%)	17 (40.5%)	55 (41.9%)
Community Based Private Practice	13 (27.1%)	18 (43.9%)	16 (38.1%)	47 (36.0%)
Underserved Geographic/Minority outreach	22 (45.8%)	27 (65.9%)	26 (61.9%)	75 (57.3%)
Number Years Clinical Practice				
<1 year	0	0	4 (9.52%)	4 (3.0%)
1-5 years	16 (33.3%)	3 (7.32%)	15 (35.7%)	34 (26.0%)
5-10 years	7 (14.6%)	5 (12.2%)	5 (11.9%)	17 (13.0%)
>10 years	25 (52.1%)	33 (80.5%)	18 (42.9%)	76 (58.0%)
Currently providing cancer risk assessment services				
Yes	38 (79.2%)	27 (65.9%)	35 (83.3%)	100 (76.3%)
No	10 (20.8%)	14 (34.1%)	7 (16.7%)	31 (23.7%)
Currently collaborating in cancer genetics research projects				
Yes	17 (35.4%)	14 (34.1%)	15 (35.7%)	46 (35.1%)
No	31 (64.6%)	27 (65.9%)	27 (64.3%)	85 (64.9%)

^aMD specialties: Surgeons 6 (12.5%), Oncologists 26 (54.2%), OB/GYNs 6 (12.5%), Geneticists 3 (6.2%), Other 7 (14.6%)

Table 2
Baseline to 14-month Post-Course Professional Self-Efficacy Outcomes (Level 4 self-assessment of competence in practice)

Professional Self-Efficacy Subscale	Data Collection Time Point	MD (n=12) Mean* (SD)	RN (n=17) Mean* (SD)	GC (n=23) Mean* (SD)	Total (n=52) Mean (SD)	p values main effect/ Interaction**
Genetics/Oncology	Baseline	4.11 (.57)	3.26 (.96)	4.11 (.61)	3.82 (.84)	<.001/ .002
	Post Phase 2	4.78 (.19)	4.40 (.59)	4.77 (.32)	4.64 (.45)	
	Post Phase 3	4.87 (.22)	4.67 (.37)	4.82 (.18)	4.78 (.28)	
Hereditary Cancer Risk Assessment	Baseline	3.21 (.85)	2.24 (1.15)	3.84 (.67)	3.17 (1.14)	<.001/ .001
	Post Phase 2	4.46 (.29)	4.00 (.61)	4.74 (.34)	4.43 (.55)	
	Post Phase 3	4.48 (.35)	4.16 (.68)	4.75 (.21)	4.50 (.52)	
Testing Strategy/Test Interpretation	Baseline	3.83 (.96)	2.93 (1.18)	4.46 (.49)	3.81 (1.10)	<.001/ <.001
	Post Phase 2	4.68 (.32)	4.19 (.75)	4.91 (.20)	4.62 (.57)	
	Post Phase 3	4.70 (.31)	4.61 (.42)	4.87 (.24)	4.75 (.34)	
Risk Management	Baseline	3.53 (.92)	2.63 (1.16)	3.34 (.94)	3.13 (1.06)	<.001/ .120
	Post Phase 2	4.53 (.55)	4.31 (.65)	4.41 (.44)	4.40 (.54)	
	Post Phase 3	4.53 (.65)	4.28 (.70)	4.51 (.27)	4.43 (.53)	
ELSI/Counseling Issues	Baseline	3.22 (1.06)	3.09 (1.09)	3.83 (.71)	3.46 (.97)	<.001/ .095
	Post Phase 2	4.17 (.54)	4.17 (.56)	4.64 (.37)	4.39 (.52)	
	Post Phase 3	4.44 (.45)	4.54 (.46)	4.63 (.37)	4.56 (.42)	
Research Collaboration	Baseline	2.70 (1.20)	2.38 (1.32)	3.03 (1.23)	2.74 (1.26)	<.001/ .232
	Post Phase 2	4.07 (.68)	3.84 (.88)	3.97 (.79)	3.95 (.79)	
	Post Phase 3	3.78 (.85)	3.83 (1.12)	3.98 (.78)	3.89 (.91)	
Overall Professional Self-Efficacy Score	Baseline	3.43 (.65)	2.76 (.99)	3.77 (.60)	3.35 (.88)	<.001/ .003
	Post Phase 2	4.45 (.30)	4.13 (.59)	4.58 (.30)	4.409 (.46)	
	Post Phase 3	4.47 (.28)	4.33 (.51)	4.59 (.19)	4.48 (.36)	

NOTE: Scores based on Likert scale ratings from 0 = No Experience/Can't Assess to 5 = Very Confident

* Mean baseline to post *Phase 2* and post *Phase 3* self-efficacy scores were significantly increased by practice discipline overall and for all six subscales ($p < .05$). By-discipline mean scores increased from Phase 2 to Phase 3 overall and in four of six subscales.

** Interaction effect (differences between disciplines over time)

Table 3

Comparisons of Baseline to 14-month-Post-Course Professional Practice Outcomes (Level 5 Performance Assessment)

Report of Professional Practice (n=57)	Data Collection Time point	Practice Endpoints Mean (SD) ^a	p values
Number of patients ^a provided cancer risk assessment in the past year	Baseline	3.61 (2.23)	.018
	Post Phase 3	4.39 (1.65)	
Number of unaffected patients ^a given information or resources for cancer prevention studies in the past year	Baseline	0.78 (1.30)	.005
	Post Phase 3	1.38 (1.24)	
Number of patients ^a enrolled in a hereditary cancer registry in the past year	Baseline	0.36 (.76)	.007
	Post Phase 3	0.85 (1.30)	
Percent “Yes”			
Provided patients high-risk screening and prevention recommendations in the past year (Yes/No)	Baseline	82.5%	.004 ^b
	Post Phase 3	98.2%	
Conducted educational outreach on topics in cancer genetics to medical professionals within the past year (Yes/No)	Baseline	45.8%	.003 ^b
	Post Phase 3	91.6%	
Conducted educational outreach on topics in cancer genetics to lay audiences within the past year (Yes/No)	Baseline	54.4%	.041 ^b
	Post Phase 3	71.9%	

^aScoring matrix for professional practice patient endpoints: 0 = no patients; 1 = 1-5 patients; 2 = 6-10 patients; 3 = 11-25 patients; 4 = 26-50 patients; 5 = 51-100 patients; 6 = >100 patients. Note: Categorical assignment was designed to maximize the chance to observe changes in trainees who are earlier in their trajectory of integrating cancer genetics services into their practices.

^bBased on McNemar test of dichotomous change over time.